Literature DB >> 15650175

Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells.

K D Ryman1, K C Meier, E M Nangle, S L Ragsdale, N L Korneeva, R E Rhoads, M R MacDonald, W B Klimstra.   

Abstract

The tropism of Sindbis virus (SB) for cells of the dendritic cell (DC) lineage and the virulence of SB in vivo are largely determined by the efficacy of alpha/beta interferon (IFN-alpha/beta)-mediated antiviral responses. These responses are essentially intact in the absence of PKR and/or RNase L (K. D. Ryman, L. J. White, R. E. Johnston, and W. B. Klimstra, Viral Immunol. 15:53-76, 2002). In the present studies, we investigated the nature of antiviral effects and identity of antiviral effectors primed by IFN-alpha/beta treatment of bone marrow-derived DCs (BMDCs) generated from mice deficient in PKR and RNase L (TD). IFN-alpha/beta priming exerted significant antiviral activity at very early stages of SB replication and most likely inhibited the initial translation of infecting genomes. The early effect targeted cap-dependent translation as protein synthesis from an SB-like and a simple RNA were inhibited by interferon treatment, but an encephalomyocarditis virus internal ribosome entry site-driven element exhibited no inhibition. Phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 was defective after virus infection of TD cells, suggesting other mechanisms of translation inhibition. To identify components of these alternative antiviral pathway(s), we have compared global gene regulation in BMDCs derived from normal 129 Sv/Ev, IFNAR1-/-, and TD mice following infection with SB or treatment with IFN-alpha/beta. Candidate effectors of alternative antiviral pathways were those genes induced by virus infection or IFN-alpha/beta treatment in 129 Sv/Ev and TD-derived BMDC but not in virus-infected or IFN-alpha/beta-treated IFNAR1-/- cells. Statistical analyses of gene array data identified 44 genes that met these criteria which are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650175      PMCID: PMC544143          DOI: 10.1128/JVI.79.3.1487-1499.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis.

Authors:  I Frolov; R Hardy; C M Rice
Journal:  RNA       Date:  2001-11       Impact factor: 4.942

2.  Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis.

Authors:  Kate D Ryman; Laura J White; Robert E Johnston; William B Klimstra
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

Review 3.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 4.  Viruses and the type I interferon antiviral system: induction and evasion.

Authors:  Christopher F Basler; Adolfo García-Sastre
Journal:  Int Rev Immunol       Date:  2002 Jul-Oct       Impact factor: 5.311

5.  Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK.

Authors:  Nicole Pavio; Patrick R Romano; Thomas M Graczyk; Stephen M Feinstone; Deborah R Taylor
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Replication of a cytopathic strain of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-mediated apoptosis of MDBK cells.

Authors:  Robert Jordan; Lijuan Wang; Thomas M Graczyk; Timothy M Block; Patrick R Romano
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Hepatitis C virus IRES-dependent translation is insensitive to an eIF2alpha-independent mechanism of inhibition by interferon in hepatocyte cell lines.

Authors:  Gennadiy Koev; Roger F Duncan; Michael M C Lai
Journal:  Virology       Date:  2002-06-05       Impact factor: 3.616

8.  Alphavirus minus-strand synthesis and persistence in mouse embryo fibroblasts derived from mice lacking RNase L and protein kinase R.

Authors:  Dorothea L Sawicki; Robert H Silverman; Bryan R Williams; Stanley G Sawicki
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins.

Authors:  Yupeng He; Wei Yan; Carlos Coito; Yu Li; Michael Gale; Michael G Katze
Journal:  J Gen Virol       Date:  2003-03       Impact factor: 3.891

10.  Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication.

Authors:  Chunfu Wang; Jill Pflugheber; Rhea Sumpter; Donald L Sodora; Daniel Hui; Ganes C Sen; Michael Gale
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  58 in total

1.  Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate.

Authors:  Christina L Gardner; Crystal W Burke; Stephen T Higgs; William B Klimstra; Kate D Ryman
Journal:  Virology       Date:  2012-02-01       Impact factor: 3.616

2.  Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.

Authors:  Pong-Yu Huang; Jih-Huong Guo; Lih-Hwa Hwang
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

3.  Viral translation is coupled to transcription in Sindbis virus-infected cells.

Authors:  Miguel A Sanz; Alfredo Castelló; Luis Carrasco
Journal:  J Virol       Date:  2007-04-18       Impact factor: 5.103

4.  Host and viral translational mechanisms during cricket paralysis virus infection.

Authors:  Julianne L Garrey; Yun-Young Lee; Hilda H T Au; Martin Bushell; Eric Jan
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

5.  ZAP inhibits murine gammaherpesvirus 68 ORF64 expression and is antagonized by RTA.

Authors:  Yifang Xuan; Danyang Gong; Jing Qi; Chuanhui Han; Hongyu Deng; Guangxia Gao
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

6.  Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling.

Authors:  Chi-You Chang; Helene Minyi Liu; Ming-Fu Chang; Shin C Chang
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Differential induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses.

Authors:  Reed S Shabman; Thomas E Morrison; Christopher Moore; Laura White; Mehul S Suthar; Linda Hueston; Nestor Rulli; Brett Lidbury; Jenny P-Y Ting; Suresh Mahalingam; Mark T Heise
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.

Authors:  Clémentine Schilte; Thérèse Couderc; Fabrice Chretien; Marion Sourisseau; Nicolas Gangneux; Florence Guivel-Benhassine; Anton Kraxner; Jürg Tschopp; Stephen Higgs; Alain Michault; Fernando Arenzana-Seisdedos; Marco Colonna; Lucie Peduto; Olivier Schwartz; Marc Lecuit; Matthew L Albert
Journal:  J Exp Med       Date:  2010-02-01       Impact factor: 14.307

9.  PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response.

Authors:  Gerald Barry; Lucy Breakwell; Rennos Fragkoudis; Ghassem Attarzadeh-Yazdi; Julio Rodriguez-Andres; Alain Kohl; John K Fazakerley
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

10.  The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses.

Authors:  Subhajit Poddar; Jennifer L Hyde; Matthew J Gorman; Michael Farzan; Michael S Diamond
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.